331 related articles for article (PubMed ID: 21466675)
1. Exploring the link between MORF4L1 and risk of breast cancer.
Martrat G; Maxwell CM; Tominaga E; Porta-de-la-Riva M; Bonifaci N; Gómez-Baldó L; Bogliolo M; Lázaro C; Blanco I; Brunet J; Aguilar H; Fernández-Rodríguez J; Seal S; Renwick A; Rahman N; Kühl J; Neveling K; Schindler D; Ramírez MJ; Castellà M; Hernández G; ; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Chu C; Davidson R; Ong KR; Cook J; Douglas F; Hodgson S; Brewer C; Morrison PJ; Porteous M; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Barile M; Viel A; Pasini B; Ottini L; Putignano AL; Savarese A; Bernard L; Radice P; Healey S; Spurdle A; Chen X; Beesley J; ; Rookus MA; Verhoef S; Tilanus-Linthorst MA; Vreeswijk MP; Asperen CJ; Bodmer D; Ausems MG; van Os TA; Blok MJ; Meijers-Heijboer HE; Hogervorst FB; ; Goldgar DE; Buys S; John EM; Miron A; Southey M; Daly MB; ; ; Harbst K; Borg A; Rantala J; Barbany-Bustinza G; Ehrencrona H; Stenmark-Askmalm M; Kaufman B; Laitman Y; Milgrom R; Friedman E; Domchek SM; Nathanson KL; Rebbeck TR; Johannsson OT; Couch FJ; Wang X; Fredericksen Z; Cuadras D; Moreno V; Pientka FK; Depping R; Caldés T; Osorio A; Benítez J; Bueren J; Heikkinen T; Nevanlinna H; Hamann U; Torres D; Caligo MA; Godwin AK; Imyanitov EN; Janavicius R; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Verny-Pierre C; Castera L; de Pauw A; Bignon YJ; Uhrhammer N; Peyrat JP; Vennin P; Ferrer SF; Collonge-Rame MA; Mortemousque I; McGuffog L; Chenevix-Trench G; Pereira-Smith OM; Antoniou AC; Cerón J; Tominaga K; Surrallés J; Pujana MA
Breast Cancer Res; 2011 Apr; 13(2):R40. PubMed ID: 21466675
[TBL] [Abstract][Full Text] [Related]
2. MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks.
Hayakawa T; Zhang F; Hayakawa N; Ohtani Y; Shinmyozu K; Nakayama J; Andreassen PR
J Cell Sci; 2010 Apr; 123(Pt 7):1124-30. PubMed ID: 20332121
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer and Fanconi anemia: what are the connections?
Zdzienicka MZ; Arwert F
Trends Mol Med; 2002 Oct; 8(10):458-60. PubMed ID: 12383764
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
[TBL] [Abstract][Full Text] [Related]
5. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
[TBL] [Abstract][Full Text] [Related]
6. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
[TBL] [Abstract][Full Text] [Related]
7. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families.
Rio Frio T; Haanpää M; Pouchet C; Pylkäs K; Vuorela M; Tischkowitz M; Winqvist R; Foulkes WD
J Hum Genet; 2010 Dec; 55(12):842-3. PubMed ID: 20844547
[TBL] [Abstract][Full Text] [Related]
9. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication.
Shen X; Do H; Li Y; Chung WH; Tomasz M; de Winter JP; Xia B; Elledge SJ; Wang W; Li L
Mol Cell; 2009 Sep; 35(5):716-23. PubMed ID: 19748364
[TBL] [Abstract][Full Text] [Related]
10. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
Zhang F; Fan Q; Ren K; Andreassen PR
Mol Cancer Res; 2009 Jul; 7(7):1110-8. PubMed ID: 19584259
[TBL] [Abstract][Full Text] [Related]
11. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Jacquemont C; Taniguchi T
Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
[TBL] [Abstract][Full Text] [Related]
12. BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells.
Wang H; Bierie B; Li AG; Pathania S; Toomire K; Dimitrov SD; Liu B; Gelman R; Giobbie-Hurder A; Feunteun J; Polyak K; Livingston DM
Mol Cell; 2016 Jul; 63(2):277-292. PubMed ID: 27373334
[TBL] [Abstract][Full Text] [Related]
13. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
[TBL] [Abstract][Full Text] [Related]
14. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
Ohashi A; Zdzienicka MZ; Chen J; Couch FJ
J Biol Chem; 2005 Apr; 280(15):14877-83. PubMed ID: 15671039
[TBL] [Abstract][Full Text] [Related]
15. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
[TBL] [Abstract][Full Text] [Related]
16. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation.
Liu Q; Ghosh P; Magpayo N; Testa M; Tang S; Gheorghiu L; Biggs P; Paganetti H; Efstathiou JA; Lu HM; Held KD; Willers H
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1081-9. PubMed ID: 25832698
[TBL] [Abstract][Full Text] [Related]
18. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2.
Godthelp BC; Wiegant WW; Waisfisz Q; Medhurst AL; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Feb; 594(1-2):39-48. PubMed ID: 16154163
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
Tacconi EM; Lai X; Folio C; Porru M; Zonderland G; Badie S; Michl J; Sechi I; Rogier M; Matía García V; Batra AS; Rueda OM; Bouwman P; Jonkers J; Ryan A; Reina-San-Martin B; Hui J; Tang N; Bruna A; Biroccio A; Tarsounas M
EMBO Mol Med; 2017 Oct; 9(10):1398-1414. PubMed ID: 28729482
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
